Read up on our latest news

Preeclampsia has a lot of underlying issues, says Aimee Corso, senior vice president of growth at Mirvie, a women's health company that has spent years publishing research on pregnancy complications that has launched its first product.

Mirvie has launched Encompass, a solution that combines a blood test to predict personalized preeclampsia risk with preventive planning tools, the company announced today.

Encompass™ combines a novel blood test to predict personalized preeclampsia risk with a preventive action plan and a responsive virtual assistant

Aimee Corso, senior vice president of growth at Mirvie, discusses the women's health company's direct-to-consumer test to help pregnant women predict preeclampsia before its onset through RNA analysis during 18 to 22 weeks of gestation.

Often detected only after symptoms appear, preeclampsia is the second leading cause of maternal death. See how the new Encompass test could help identify risk earlier and save lives.

Mirvie Inc. continues the development of precision medicine for pregnancy-related conditions with its Encompass blood test to predict preeclampsia risk and individualized support to head off the life-threatening complication that affects one in 12 pregnancies.

The first and only at-home blood test that predicts a pregnant person’s risk of developing preeclampsia has launched. Known as Encompass, the test from Mirvie can predict the condition months before symptoms appear, giving pregnant people time to take preventative steps.

Until recently, preeclampsia could only be diagnosed after symptoms appeared. But now, researchers are exploring ways to predict risk earlier. A newly launched at-home blood test, Encompass™, is one of the latest tools being studied to give families and providers a potential early warning—months before symptoms might develop.

New tools like Encompass™ by Mirvie let you predict your personal risk for preeclampsia months before symptoms appear. It’s a simple at-home blood test you take between 18–22 weeks, and it uses groundbreaking RNA science to analyze thousands of signals from you, your baby, and the placenta.

Research led by Mirvie Inc. has discovered a molecular signal in blood samples that can predict preeclampsia and related conditions months before clinical symptoms appear.